CervoMed Inc. - 8-K Filing
CervoMed reports Q3 2026 net loss of $5.9 million and maintains cash runway through Q3 2027. (Items: 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or, 9.01 Financial Statements and Exhibits)
Tickers: $CRVO
Read the full article at SEC EDGAR
Part of the story TREDEGAR CORP - 8-K Filing (3 articles)